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ABSTRACT
Objectives: The aim of this study is to assess the cost-effectiveness of 21
alternative cervical cancer screening (CCS) strategies.
Methods: A cohort simulation model was developed to determine from a
health systems perspective the cost-effectiveness of the 21 alternative CCS
strategies that incorporated combinations of Papanicolaou’s smear test
(PAP), liquid-based cytology (LBC) or human papillomavirus deoxyribo-
nucleic acid (HPV-DNA) testing. The model was calibrated to categorize
total costs into four budgetary authorities: testing, physician, inpatient, and
outpatient services. Within each category, alternative screening strategies
were contrasted in terms of their cost impacts and the percent change
calculated within each category. Epidemiologic data and costs were derived
from administrative health databases. Estimates of test characteristics and
quality-adjusted life years (QALYs) were derived from available literature.
Results: Three-year screening with PAP and HPV-DNA triage testing for
women older than 30 years of age (3-year PAP + HPV + PAP-age) is less
costly and more effective saving $16,078 per additional QALY gained.
Although there was an associated net cost decrease of 4.2% driven by a
reduction in testing and physician costs of 22.1% and 18.6%, respectively,
there is a cost increase of 0.8% and 27.7% in inpatient and outpatient
services, respectively.
Conclusion: There is economic evidence to support adopting 3-year
PAP + HPV + PAP-age. Budgetary resources can potentially be shifted
from testing and physician services to fund the additional resource require-
ments for inpatient and outpatient services.
Keywords: cancer, cost-effectiveness analysis, economic evaluation,
Markov model.
Introduction
Cervical cancer (CC) is considered a largely preventable disease
through the detection, treatment, and follow-up of its precursors
such as human papillomavirus (HPV) and cervical intraepithelial
neoplasia (CIN) (i.e., precancerous lesions on the cervix) [1–3].
Conventional cervical cytology (Papanicolaou’s smear test—
PAP) has been used for more than 50 years to detect CC and its
precursors in industrialized countries [4]. Newer assays have
been developed that include liquid-based cytology (LBC) and
HPV deoxyribonucleic acid (DNA) testing (HPV-DNA). Com-
pared to PAP, LBC is more sensitive and provides greater consis-
tency in the quality of the tissue sample used for cytological
analysis [3]. Alternatively, HPV-DNA is a molecular assay that
can be used to detect the presence of high-risk oncogenetic strains
of HPV (only high-risk oncogenetic HPV strains potentially lead
to CC).
Both the LBC and HPV-DNA assays offer promise in provid-
ing more effective CC screening algorithms but both are associ-
ated with a higher cost per test. The objective was to conduct
an economic evaluation to determine the cost-effectiveness of
alternative CC screening strategies employing LBC and/or
HPV-DNA.
Methods
Screening Alternatives
There were seven alternative screening and testing algorithms
(contact the author for ﬂow diagrams). Each alternative was
evaluated at 1-, 2-, and 3-year screening intervals giving a total of
21 alternatives.
PAP + PAP (current). Women aged 18 to 69 are routinely
screened annually with PAP. There are seven potential cytological
results from a PAP test (presented in order of increasing severity):
unsatisfactory specimen (i.e., specimen is insufﬁcient for analy-
sis); negative; atypical squamous cells of undetermined signiﬁ-
cance (ASCUS); low-grade squamous intraepithelial lesion
(LSIL); atypical squamous cells, cannot exclude (ASCH); atypical
glandular cells (AGC); and high-grade squamous intraepithelial
lesion (HSIL). Women with unsatisfactory specimens are
requested to have a repeat PAP test every 3 months until a
satisfactory specimen is obtained while women with negative
results return to routine screening.
Women with ASCH, AGC, or HSIL are immediately referred
for colposcopy and biopsy for histologic assessment of the cervix.
Based on the histologic assessment, women with CIN (i.e.,
lesions) graded as CIN1 or less receive another colposcopy/
biopsy in 6 months and if the results are again graded as CIN1 or
less they return to routine screening. Women with CIN graded
greater than CIN1 (i.e., CIN2 or CIN3) have the CIN removed
by a conization procedure and receive a hysterectomy.
Women with ASCUS or LSIL are retested with PAP in 6
months. Women with an unsatisfactory specimen are requested
to have a repeat PAP test every 3 months until a satisfactory
specimen is obtained. Women with ASCUS or greater are imme-
diately referred for colposcopy and biopsy and follow the histo-
logic assessment described above. Women with negative results
are retested with PAP in 6 months and the follow-up process is
repeated three times (total of 2 years of follow-up). Women who
repeatedly test negative at the end of their 2-year follow-up
return to routine screening.
PAP + HPV + PAP. The screening and testing protocol is identi-
cal to that of PAP + PAP with one exception. Women with
ASCUS are contacted to have an HPV-DNA as a triage test for
the presence of high-risk oncogenetic HPV (note that women
return to the clinic). Women with negative results for high-risk
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HPV return to routine screening while women with positive
results are immediately referred for colposcopy and biopsy.
PAP + HPV + PAP-age (age restriction). The screening and
testing protocol is identical to that of PAP + HPV + PAP with one
exception. Only women 30 years of age or older who have
ASCUS receive a HPV-DNA triage test.
LBC + HPV + LBC. The screening and testing protocol is iden-
tical to that of PAP + HPV + PAP with two exceptions. First,
routine screening is conducted with LBC. Second, women with
LSIL are retested with LBC in 6 months instead of PAP.
LBC + HPV + LBC-age (age restriction). The screening and
testing protocol is identical to that of LBC + HPV + LBC with
one exception. Only women 30 years of age or older who have
ASCUS receive a HPV-DNA triage test.
HPV + LBC + HPV/LBC. Women aged 18 to 69 are routinely
screened with HPV-DNA. Women who test negative for high-risk
oncogenetic HPV return to routine screening conducted every 3
years while women who test positive for high-risk oncogenetic
HPV receive an LBC triage test. Women with an unsatisfactory
specimen are requested to have a repeat LBC test every 3 months
until a satisfactory specimen is obtained. Women with negative
results return to routine screening. Women with ASCH, AGC, or
HSIL are immediately referred for colposcopy and biopsy for
histologic assessment of their cervix identical to that described
for PAP + PAP.
Women with ASCUS or LSIL are retested with both LBC and
HPV-DNA in 6 months. Women who test negative for high-risk
oncogenetic HPV and who have a negative, unsatisfactory
ASCUS or LSIL result on LBC return to routine screening con-
ducting every 3 years. Women who test positive for high-risk
oncogenetic HPV and who have ASCH, AGC, or HSIL on LBC
are immediately referred to colposcopy and biopsy for histologic
assessment of their cervix identical to that described for
PAP + PAP. Women who test positive for high-risk oncogenetic
HPV and who have a negative, unsatisfactory, ASCUS or LSIL
result on LBC are retested with LBC and HPV-DNA in 6 months
with the follow-up process repeated three times (total of 2 years
of follow-up). Women who repeatedly test positive for high-risk
oncogenetic HPV and who have a negative, unsatisfactory,
ASCUS or LSIL result on LBC are retested with LBC at the end
of their 2-year follow-up are immediately referred to colposcopy
and biopsy for histologic assessment of their cervix identical to
that described for PAP + PAP.
HPV + LBC + HPV/LBC-age (age restriction). The screening
and testing protocol is identical to HPV + LBC + HPV/LBC with
the exception that only women 30 years of age or older receive a
HPV-DNA test for primary screening. Women younger than 30
years of age receive LBC + HPV + LBC.
Economic Evaluation
A cohort simulation Markov model was developed to determine
from a health systems perspective (i.e., health ministry) the cost-
effectiveness of the 21 alternative CC screening strategies in
terms of both their costs and health outcomes. All analyses were
conducted using Microsoft Excel 2003 and TreeAge Pro Suite
(TREEAGE Software Inc; Williamstown, MA, USA).
Model
The model was based on the progression of HPV and CC car-
cinogenesis illustrated in Figure 1 (epidemiologic model). The
Well
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Figure 1 Progression of human papillomavirus (HPV) and cervix carcinogenesis. CIN, cervical intraepithelial neoplasia.
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model starts with women 12 years of age in the well state (clear
of infection) and as they increase in age, they can acquire low-
risk HPV (i.e., will never develop into CC) or high-risk oncoge-
netic HPV (i.e., can potentially develop into CC). The cohort was
followed until age 80. Each cycle in the model represents 1 year.
Each year, age-dependent probabilities for death (all cause) and
hysterectomy are applied and these women are censored from
further analysis (i.e., removed from the pool at risk). The remain-
ing women either remain in their current health state or transi-
tion to another health state.
Once infected with HPV, CIN on the cervix can develop,
which range in severity from CIN1 to CIN2/3. Only CIN caused
by a high-risk oncogenetic HPV strain can potentially lead to CC.
However, prior to CC, the condition can spontaneously regress
to a lesser severity or clear completely. Women who clear the
HPV infection are assumed to develop an immunologic response,
thereby reducing their chance of future infection. Once CC devel-
ops, no regression can occur to a better health state and in each
year a cancer-speciﬁc mortality rate is applied. However, CC
mortality rates differ between women with detected and treated
cancers compared to women with undetected and untreated
cancers. Treatment for cancer consists of conization, hysterec-
tomy, pelvic lymphadenectomy (removal of the pelvic lymph
nodes), chemotherapy, and radiation. Women surviving for
longer than 5 years after CC treatment are considered cured but
do not return to routine screening.
Each screening and testing algorithm is applied to the epide-
miologic model. Depending on the screening interval and age of
the women (screening does not begin until age 18), age-speciﬁc
coverage rates are applied to determine the number of women
who will receive primary screening. Women who are not screened
continue to progress and regress into other health states. Women
who are screened also continue to progress and regress into other
health states while progressing through the screening and testing
algorithm. Hence, progression through the screening/testing
algorithm are dependent on the health status at the time the test
was applied (e.g., well, CIN2/3, and cancer), the sensitivity and
speciﬁcities of the various tests, the speciﬁc testing algorithm and
the number of women who are not lost to follow-up (i.e., com-
pliance). For example, for women with no histologic abnormali-
ties (i.e., <CIN1) a result of ASCUS or worse on PAP or LBC is
a false positive. However, in the following years she may get
infected with HPV and develop CIN2/3, and if tested again, a
result of ASCUS or worse on PAP or LBC is considered a true
positive. Alternatively, if her CIN2/3 was caused by low-risk
HPV strain, and she was tested with HPV, a positive result is a
false positive. Alternatively, if her CIN2/3 were caused by a
high-risk oncogenetic HPV strain, a positive result is a true
positive.
Furthermore, at 2- and 3-year screening intervals, women
who are not screened (i.e., missed) return to routine screening
using 1-year screening intervals and 1-year coverage rates, given
that these women are eligible to receive screening immediately. It
is important to note that in the model, women who are incom-
pliant with follow-up or women who receive two sequential
unsatisfactory samples are assumed to return to routine screen-
ing. It is also assumed that colposcopy and biopsy is the diag-
nostic gold standard for conﬁrming the presence and grade of
CIN and the presence and severity of CC.
Hence, based on the characteristics of each test (e.g., sensi-
tivity and speciﬁcity) and when they are applied in each algo-
rithm, the testing and diagnostic outcomes for women as they
progress and regress in HPV infection over time is generated.
Therefore the differences in the test characteristics of each test
and how each test is applied in each algorithm will generate a
different set of costs and health outcomes and forms the basis of
the comparative analysis.
Model inputs. All modeling assumptions and their sources are
shown in Tables 1 and 2. The simulation model was based on the
underlying epidemiology associated with the progression of HPV
and CC carcinogenesis. Alberta-speciﬁc epidemiologic data
included CC incidence, CC prevalence, and aggregated CC mor-
tality. There was no Alberta-speciﬁc data on the incidence of
HPV infection and age-speciﬁc high-risk HPV incidence rates
were derived from the published Canadian literature [3]. Obtain-
ing Alberta-speciﬁc incidence rates for high-risk oncogenetic
HPV infection was generated by recalibrating the HPV incidence
rates (obtained from the literature) to match the CC prevalence
rates generated by the model to actual Alberta CC prevalence
data. This process was conducted iteratively under the current
Alberta screening/testing algorithm (i.e., 1-year PAP + PAP) until
the estimated age speciﬁc CC prevalence rates from the model
matched closely with the actual CC prevalence rates of Alberta.
Furthermore, although Alberta-speciﬁc CC mortality was
available, it did not differentiate the increase risk in mortality as
CC increased in severity (i.e., Stage 1 CC vs. Stage 4 CC).
Stage-speciﬁc CC mortality rates were derived from the pub-
lished Canadian literature [3]. Obtaining Alberta-speciﬁc mortal-
ity rates was generated by recalibrating stage-speciﬁc CC
mortality rates to match the CC mortality rates generated from
the model to the aggregate Alberta-speciﬁc CC mortality data.
Costs. All costs were made to reﬂect 2007 Canadian dollars and
discounted at a rate of 5%. Testing costs were provided by
Calgary Laboratory Services and Capital Health. Physician, Out-
patient, and Inpatient costs for other diagnostic procedures and
treatments were extracted from three Alberta provincial health
ministry databases. The Alberta Physician Claims database pro-
vided information related to billing services and ministry pay-
ments to physicians for medically insured services in Alberta. For
2004–2005, physician cost data for procedures related to CC
screening/testing were provided based on physician fee codes
associated with CC screening/testing. However, for each service
event, other procedures listed with the CC screening/testing pro-
cedures were recorded and an average cost for the procedure
related to CC screening/testing calculated. The objective was to
obtain the most representative cost estimate for the services
associated with CC screening/testing and including other proce-
dures listed ensured that the analysis account for physicians
routinely conducting and billing for other services that accom-
pany the procedure of interest.
Physician fee codes were then used to identify procedures and
costs related to CC screening/testing for outpatient and inpatient
services using a conversion table that translated the physician fee
codes into their corresponding outpatient and inpatient service
codes. The Alberta Discharge Abstracts database provided cost
information related to hospital inpatient procedures while the
Ambulatory Care Classiﬁcation database provided cost informa-
tion related to outpatient procedures for 2004–2005. In both
databases, for each service event, other procedures listed with the
CC screening/testing procedures were recorded and an average
cost for the procedure related to CC screening/testing calculated.
Outcomes. Quality-adjusted life years (QALYs) were used as the
primary measurement for assessing cost-effectiveness between
the alternative screening/testing algorithms. CC cases, CC
deaths, and QALY are interrelated in that a greater number
CC cases will be positively associated with a greater number of
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CC deaths with both contributing to reduce the total number of
QALYs. QALYs were discounted at a rate of 3%.
Model simulations and uncertainty. It is important to provide
information regarding the degree of variability (i.e., uncertainty)
in potential costs and effectiveness to enable decision makers to
evaluate the credible range of potential costs and outcomes.
Expected values of costs and effectiveness were calculated from
6000 Monte Carlo simulations using the distributions and stan-
dard errors listed in Table 2. During each simulation, for each
input with a ﬁtted distribution, a value is randomly sampled from
the distribution and the costs and effectiveness were calculated
for the simulation (probabilistic sensitivity analysis). Based on
the 6000 sample sets, a distribution of expected costs and effec-
tiveness for each alternative is generated from which the degree
of uncertainty is assessed.
Criteria for cost-effectiveness. Both a health economic and a CC
screening policy perspective were used to determine cost-
effectiveness. Alternatives that were less effective than the current
algorithm were not considered cost-effective because they would
increase CC cases and deaths. That is, from a CC screening
policy perspective, alternatives that generate greater CC cases
and deaths were unacceptable alternatives. Alternatives that were
less costly and more effective compared to other alternatives were
considered cost-effective. The cost-effectiveness of alternatives
that were more costly and more effective were deemed uncertain
because they are ultimately dependent on whether decision
makers deem the additional effectiveness is worth the additional
cost; although $50,000 per additional QALY gained was used as
a relative benchmark.
Cost attribution analysis. Cost attribution analysis (CAA) is an
approach that examines the systematic differences in costs
between alternatives to not only elucidate the relative resource
implications on disparate health sectors but to also identify the
cost drivers (i.e., cost attributing) driving the cost differences. Pre-
senting conventional economic evaluation results (e.g., incremen-
tal cost-effectiveness ratio [ICER]) with information generated via
CAA would provide decision makers with information that iden-
tiﬁes cost-effective alternatives while also providing insight into
where resources from within the system can be potentially shifted
to facilitate the adoption of the cost-effective alternative.
There are four primary budgetary areas related to CC screen-
ing. These are resources related to the screening tests (including
primary and follow-up testing), physician consultations, outpa-
tient procedures (e.g., colposcopies, biopsies, and conizations),
and inpatient procedures (e.g., cancer treatment). Accordingly,
the model was calibrated to track and categorize costs by these
budgetary categories. Within each category, alternative screening
strategies were contrasted in terms of their cost impacts and the
percent change calculated within each category.
Results
All costs are expressed in 2007 Canadian dollars. All results are
per woman.
Economic Evaluation
Figure 2 shows the relative cost-effectiveness between the 21 CC
screening/testing algorithms evaluated. Compared to the current
Alberta screening/testing algorithm of 1-year PAP + PAP, algo-
rithms that were more effective included: 3-year LBC + HPV +
LBC-age; 3-year PAP + HPV + PAP-age; 1-, 2-, and 3-year
LBC + HPV + LBC; 1 and 2-year LBC + HPV + LBC-age; 1-, 2-Ta
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Table 2 Model inputs
Model parameters Input SE or range Distribution* Source
Cervical cancer (CC) screening program
Screening follow up participation rate 0.76 0.5–0.9 Uniform [3]
Natural progression of HPV infection
From HPV low-risk strain to:
CIN1 low-risk strain 0.028 0.01–0.046 Uniform [16]
CIN2/3 low-risk strain (<35 years old) 0.0035 0.001–0.006 Uniform [17]
CIN2/3 low-risk strain (35 years old) 0.0145 0.004–0.025 Uniform [17]
Well/clear 0.126 0.018–0.233 Uniform [16]
From HPV high-risk strain to:
CIN1 high-risk strain 0.045 0.01–0.08 Uniform [16]
CIN2/3 high-risk strain (<35 years old) 0.0035 0.001–0.006 Uniform [17]
CIN2/3 high-risk strain (35 years old) 0.0145 0.004–0.025 Uniform [17]
Well/clear 0.126 0.018–0.234 Uniform [16]
From CIN1 low-risk strain to:
CIN2/3 low-risk strain 0.045 0.04–0.05 Uniform [16]
HPV low-risk strain 0.101 0.085–0.116 Uniform [3]
Well/clear 0.325 0.11–0.54 Uniform [3]
From CIN1 high-risk strain to:
CIN2/3 high-risk strain 0.10 0.08–0.12 Uniform [16]
HPV high-risk strain 0.112 0.062–0.162 Uniform [3]
Well/clear 0.325 0.11–0.54 Uniform [3]
From CIN2/3 low-risk strain
CIN1 low-risk strain 0.068 0.023–0.113 Uniform [3]
HPV low-risk strain 0.02 0.01–0.03 Uniform [3]
Well/clear 0.002 0.001–0.003 Uniform [3]
From CIN2/3 high-risk strain
CIN1 high-risk strain 0.017 0–0.034 Uniform [3]
HPV high-risk strain 0.02 0.01–0.03 Uniform [3]
Well/clear 0.002 0.001–0.003 Uniform [3]
From CC
Stage 1 to stage 2 0.148 0.212–0.340 Uniform [17]
Stage 2 to stage 3 0.293 0.226–0.360 Uniform [17]
Stage 3 to stage 4 0.397 0.309–0.484 Uniform [17]
Partial immunity to HPV low risk after clearance 0.61 0.32–0.90 Uniform [3]
Partial immunity to HPV high risk after clearance 0.38 0.18–0.58 Uniform [3]
Characteristics of CC
Symptomatic stage 1 0.144 0.109–0.179 Uniform [17]
Symptomatic stage 2 0.212 0.162–0.261 Uniform [17]
Symptomatic stage 3 0.504 0.399–0.609 Uniform [17]
Symptomatic stage 4 0.685 0.561–0.809 Uniform [17]
Stage 1 survival with treatment† 0.997 0.993–1 Uniform [17]
Stage 2 survival with treatment† 0.982 0.973–0.991 Uniform [17]
Stage 3 survival with treatment† 0.831 0.771–0.890 Uniform [17]
Stage 4 survival with treatment† 0.627 0.596–0.657 Uniform [17]
Adjustment for survival—without treatment 0.03 — None ‡
Characteristics of screening tests and treatment
PAP sensitivity 0.74 0.055 Beta [3]
When in stage CIN1
ASCUS 0.364 — None [3]
LSIL 0.461 — None [3]
HSIL 0.1758 — None [3]
When in stage CIN2/3 or invasive cancer
ASCUS 0.173 — None [3]
LSIL 0.244 — None [3]
HSIL 0.583 — None [3]
PAP speciﬁcity 0.868 0.064 Beta [3]
Has no histological abnormalities
False ASCUS 0.682 — None [3]
False LSIL 0.242 — None [3]
False HSIL 0.076 — None [3]
Proportion of inadequate samples 0.0058 0.0001 Beta [3]
LBC sensitivity (difference between LBC–CC) 0.0643 0.064 Normal [3]
When in stage CIN1
ASCUS 0.364 — None [3]
LSIL 0.461 — None [3]
HSIL 0.176 — None [3]
When in stage CIN2/3 or invasive cancer
ASCUS 0.173 — None [3]
LSIL 0.244 — None [3]
HSIL 0.583 — None [3]
LBC speciﬁcity -0.0402 0.081 Uniform [3]
Has no histological abnormalities
False ASCUS 0.682
False LSIL 0.242
False HSIL 0.075
Proportion of inadequate samples 0.0024 0.0001 Beta [3]
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Table 2 Continued
Model parameters Input SE or range Distribution* Source
HPV hybrid II
Sensitivity high-risk strain 30 years 0.948 0.020 Beta [18]
Speciﬁcity high-risk absence 30 years 0.860 0.021 Beta [18]
Sensitivity ratio high-risk strain <30 years§ 1.070 0.046 Gamma [18]
Speciﬁcity ratio high-risk absence <30 years§ 0.860 0.021 Gamma [18]
Treatment effectiveness
Loop electrical excision procedure (LEEP) conization 0.964 0.014 Beta [19]
Outcomes—quality-adjusted life years
Well/clear (age-speciﬁc, refer to Table 1)
CIN1 0.91 — None [3]
CIN2/3 0.87 — None [3]
Cervical cancer stage 1 without treatment 0.65 0.49–0.81 Uniform [3]
Cervical cancer stage 2 without treatment 0.67 0.44–0.90 Uniform [3]
Cervical cancer stage 3 without treatment 0.56 0.42–0.70 Uniform [3]
Cervical cancer stage 4 without treatment 0.48 0.36–0.60 Uniform [3]
Cervical cancer stage 1 with treatment 0.86 0.73–0.99 Uniform [3]
Cervical cancer stage 2 with treatment 0.83 0.68–0.98 Uniform [3]
Cervical cancer stage 3 with treatment 0.83 0.68–0.98 Uniform [3]
Cervical cancer stage 4 with treatment 0.63 0.47–0.78 Uniform [3]
Outcomes discount rate 0.03 — NA
Costs
General practitioner visit $82.58 — None [20]
Chest x-ray $120 — None [20]
Tests and diagnostics
PAP (labor, equipment, supplies) $22.00 — None ||
LBC (labor, equipment, supplies) $14.36 — None ¶
HPV (labor, equipment, supplies) $40.76 — None ¶
Colposcopy (none are conducted as inpatient)
Physician $50.42 $15.77 Gamma #
Outpatient $294.70 $191.97 Gamma **
Cone biopsy
Physician $31.13 $11.4 Gamma #
Outpatient (none are conducted as inpatient) $270.72 $78.45 Gamma **
Punch biopsy
Physician $127.96 $31.29 Gamma #
Outpatient (none are conducted as inpatient) $276.01 $128.61 Gamma **
Proportion conducted as punch 0.85 — None #
CO2 laser therapy
Physician $119.25 $23.52 Gamma #
Outpatient (none are conducted as inpatient) $211.16 $178.28 Gamma **
LEEP
Physician $118.18 $13.30 Gamma #
Outpatient (none are conducted as inpatient) $295.52 $174.51 Gamma **
Proportion conducted as LEEP 0.73 — None #
Chemotherapy
Physician $257.23 $245.38 Gamma #
Inpatient (none are conducted as outpatient) $13,800.33 $8,415.18 Gamma ††
Radiation
Physician $374.05 $297.93 Gamma #
Inpatient (none are conducted as outpatient) $10,838.41 $8,374.97 Gamma ††
Pelvic lymphadenectomy
Physician $267.63 $122.26 Gamma #
Inpatient (none are conducted as outpatient) $7,314.70 $1,146.56 Gamma ††
Hysterectomy
Physician $356.36 $173.19 Gamma #
Outpatient $816.97 $488.08 Gamma **
Inpatient $4,597.93 $2,655.69 Gamma ††
Proportion done as inpatient 0.45 — None ††
End-of-life cost for cancer (1 year prior to death) $44,070 $22,035–$88,140 Uniform [3]
Cost discount rate 0.05 — NA
*Refers to the mathematical distribution assigned to incorporate the likelihood of possible values (i.e., inherent variance) of the input during model simulation.“None” means that input does
not vary during model simulation.Distributions are ﬁtted based on primary data. In general, parameters estimated from larger sample sizes generate smaller ranges of possible values (consistent
with statistical theory).Therefore inputs with very small standard errors (SE) indicate they were ﬁtted from large sample sizes.
†Original values were adjusted to generate Alberta-speciﬁc mortality rates during model validation Final adjusted values are shown.
‡The Alberta Cancer Board Alberta Registry Database (September 2008). Derived by comparing women who received immediate initial treatment with women who whose initial treatment
information show “none,” “refuse,” “unknown,” “observation,” or missing in Alberta Cancer Registry databases.
§Sensitivity and speciﬁcity for women under 30 years of age is calculated by dividing the sensitivity and speciﬁcity for women 30 years of age by the ratio.
||Calgary Laboratory Services Accounting Records, pers. comm., 2008.
¶Capital Health Laboratories Planning Information, pers. comm., 2008.
#Alberta Health and Wellness Physician Claims Data Base 2004–2005.Values were adjusted to reﬂect 2007 Canadian dollars using the Consumer Price Index.
**Alberta Health and Wellness Ambulatory Care Classiﬁcation System 2004–2005.Values were adjusted to reﬂect 2007 Canadian dollars using the Consumer Price Index.
††Alberta Health and Wellness Discharge Abstracts Database 2004–2005.Values were adjusted to reﬂect 2007 Canadian dollars using the Consumer Price Index.
ASCUS, atypical squamous cells of undetermined signiﬁcance;CIN, cervical intraepithelial neoplasia;HPV,human papillomavirus;HSIL, high-grade squamous intraepithelial lesion; LBC, liquid-based
cytology; LSIL, low-grade squamous intraepithelial lesion; NA, not applicable; PAP, Papanicolaou’s smear test.
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and 3-year PAP + HPV + PAP; and 1- and 2-year PAP + HPV +
PAP-age.
Of the algorithms that generated greater effectiveness, 2- and
3-year PAP + HPV + PAP, 2-year PAP + HPV + PAP-age, 2- and
3-year LBC + HPV + LBC, and 1-, 2-, and 3-year LBC + HPV +
LBC-age were extended dominated (i.e., dominated by other
algorithms that provided equal effectiveness at a cheaper cost)
(Fig. 3). Compared to 1-year PAP + PAP, 3-year PAP + HPV +
PAP-age will save $16,078 per additional QALY gained. Subse-
quently, 1-year PAP + HPV + PAP-age, 1-year PAP + HPV + PAP,
and 1-year LBC + HPV + LBC will cost $58,512, $86,266, and
$127,076 per additional QALY gained, respectively.
Uncertainty. Greater than 98% of simulations for 2- and 3-year
PAP + PAP and 1-, 2-, and 3-year HPV + LBC + HPV/LBC-age
were less costly and less effective (Fig. 4) compared to 1-year
PAP + PAP. Greater than 60% of simulations for 1-, 2-, and
3-year PAP + HPV + PAP; 1-year PAP + HPV + PAP-age; 1-, 2-,
and 3-year-LBC + HPV + LBC; and 1- and 2-year LBC + HPV +
LBC-age were more costly and more effective. Greater than 88%
of simulations for 1-, 2-, and 3-year HPV + LBC + HPV/LBC
were less effective and more costly. For 3-year PAP + HPV + PAP-
age and 3-year LBC + HPV + LBC-age, 63% and 45%, respec-
tively, were less costly and more effective.
Differential Resource Impacts
Figure 5 shows the incremental cost between 1-year PAP + PAP
and the alternative algorithms that were equally or more
PAP: PAP+PAP (CURRENT) 
PAPHPV: PAP+HPV+PAP                     
PAPHPVage: PAP+HPV+PAP-age 
LBC: LBC+HPV+LBC 
LBCage: LBC+HPV+LBC-age  
HPV: HPV+LBC+HPV/LBC  
HPVage: HPV+LBC+HPV/LBC-age. 
Figure 2 Cost-effectiveness of alternative cervical cancer screening and testing algorithms. HPV, human papillomavirus; LBC, liquid-based cytology; PAP, Papanico-
laou’s smear test; QALYs, quality-assisted life years. Shaded areas indicate those alternatives that are extended dominated.The different symbols are to differentiate
the alternatives.
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effectively separated into four cost categories: testing, physician,
inpatient, and outpatient services. Three-year PAP + HPV + PAP-
age are estimated to generate a net cost decrease of 4.2%. The net
cost decrease is completely driven by a reduction in testing and
physician costs of 22.1% and 18.6%, respectively. There is a cost
increase of 0.8% and 27.7% in inpatient and outpatient services,
respectively. Three-year LBC + HPV + LBC-age are estimated to
generate a cost decrease of 0.3%. The net cost decrease is com-
pletely driven by a reduction of 19.4% in physician services.
There is a cost increase of 19.6% in testing, 0.9% in inpatient,
and 30% in outpatient services. PAP + HPV + PAP and LBC +
HPV + LBC at all screening intervals, and PAP + HPV + PAP and
LBC + HPV + LBC at 1- and 2-year screening intervals, are esti-
mated to generate a net cost increase. There are no cost decreases
to any cost categories.
Discussion
Value for Money
After eliminating alternatives that were not cost-effective or
unacceptable from a CC program policy perspective, four alter-
natives remained for ﬁnal consideration, which includes (listed in
order of increasing effectiveness): 3-year PAP + HPV + PAP-age,
1-year PAP + HPV + PAP-age, 1-year PAP + HPV + PAP, and
1-year LBC + HPV + LBC. Compared to the current Alberta CC
screening/testing algorithm, 3-year PAP + HPV + PAP-age was
less costly and more effective translating in a cost saving of
–$16,078 per additional QALY gained per women. Thus, 3-year
PAP + HPV + PAP-age are cost-effective.
Achieving subsequent levels of effectiveness would require
switching to 1-year PAP + HPV + PAP-age followed by 1-year
PAP: PAP+PAP (CURRENT) 
PAPHPV: PAP+HPV+PAP                     
PAPHPVage: PAP+HPV+PAP-age 
LBC: LBC+HPV+LBC 
LBCage: LBC+HPV+LBC-age  
Figure 3 Cost-efﬁciency curve of alternative cervical cancer screening and testing algorithms. HPV, human papillomavirus; LBC, liquid-based cytology; PAP,
Papanicolaou’s smear test; QALYs, quality-assisted life years. Shaded areas indicate those alternatives that are extended dominated. The different symbols are to
differentiate the alternatives.
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PAP + HPV + PAP and 1-year LBC + HPV + LBC with ICERs of
$58,512, $86,266, and $127,076, respectively, per additional
QALY gained per women. Whether these are cost-effective is
dependent on whether decision makers deem the additional
health gain worth the additional cost. However, these ICERs
exceed conventional cost-effectiveness thresholds suggested in
the health economic literature (e.g., $50,000 per additional
QALY gained).
Affordability and Policy Implications
Several economic evaluations comparing alternative CC screen-
ing algorithms have been published in the extant literature
[5–14]. While these studies identify whether alternatives are
more/less costly and more/less effective, they do not provide any
indication of the resource impacts to disparate sectors of the
health system from which decision makers can use to strategize
PAP: PAP+PAP (CURRENT) 
PAPHPV: PAP+HPV+PAP
PAPHPVage: PAP+HPV+PAP-age 
LBC: LBC+HPV+LBC 
LBCage: LBC+HPV+LBC-age  
HPV: HPV+LBC+HPV/LBC
HPVage: HPV+LBC+HPV/LBC-age  
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Figure 4 Distribution of incremental costs and outcomes of alternative cervical cancer screening and testing algorithms compared to the currentAlberta screening
algorithm (1-year PAP + PAP). Six thousand Monte Carlo simulations were conducted for each screening/testing algorithm. For each simulation, incremental costs and
effectiveness were calculated between the current Alberta Screening/Testing algorithm and the other 21 alternative screening/testing algorithms being considered.
The graph illustrates the percentage of simulation falling in each quadrant (northwest [NW], northeast [NE], southeast [SE], and southwest [SW]) on the incremental
cost-effectiveness plane. Costs and outcomes are discounted at 5% and 3%, respectively. HPV, human papillomavirus; LBC, liquid-based cytology; PAP, Papanicolaou’s
smear test; QALYs, quality-assisted life years.
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around potential resource shifting. Although 3-year PAP +
HPV + PAP-age was found to generate a 4.2% decrease in total
costs, decision makers should be cognizant of the cost increases
of 0.8% and 27.7% to inpatient and outpatient services, respec-
tively. Budgetary resources can potentially be shifted from testing
and physician services to fund the additional resource require-
ments for inpatient and outpatient services.
Study Limitations
The results however, should be evaluated in light of the following
limitations. First, the results are entirely founded on the screening
and testing algorithms outlined in this report. Yet, it is uncertain
how clinicians will ultimately use these tests. Although in actual
conditions there will be variation in how these tests are used
depending on clinical presentation and patient history, the
screening/testing algorithms outlined in this report should be
adhered to the greatest extent clinically permissible in order to
achieve the economic and health outcomes described. Still, it is
important to note that the analysis was based on Canadian costs
that limit the generalizability of results to other health settings.
Second, uniform distributions were used to characterize the
transition probabilities from CIN to CC because the extant lit-
erature provided ranges opposed to actual empirical data from
which a distributional form could be ﬁtted to the parameters.
Consequently, the transition probabilities may not be represen-
tative of the transition probabilities that characterizes CC car-
cinogenesis. Nonetheless, the probabilistic sensitivity analysis did
indicate that the results were consistent.
Third, women undergoing cancer screening may not receive
any beneﬁt and may in fact be exposed to iatrogenic health risks
(e.g., unnecessary invasive follow-up procedures resulting from
either false positive biopsies or CIN graded 2 or 3 that would
have naturally regressed) [15]. The costs and health outcomes
associated with iatrogenic events were not considered in the
analysis because colposcopy-guided biopsy was considered the
gold standard in actual clinical practice.
Conclusion
There are tradeoffs in costs and improvement in health outcomes
associated with each CC screening/testing algorithm. For
instance, increasing screening interval decreases total costs but
results in greater CC cases and deaths. LBC and HPV have a
higher sensitivity but lower speciﬁcity than PAP, resulting in
PAPHPV: PAP+HPV+PAP                    
PAPHPVage: PAP+HPV+PAP-age
LBC: LBC+HPV+LBC
LBCage: LBC+HPV+LBC-age 
Figure 5 Percent change (compared to 1-year PAP + PAP) in costs by budgetary category.HPV, human papillomavirus; LBC, liquid-based cytology; PAP, Papanicolaou’s
smear test.
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increased follow-up and conﬁrmatory testing of both appropriate
(true positive) and inappropriate (false positive) referrals. Iden-
tifying the CC screening/testing algorithm that provides the best
balance between costs and improvements in health outcomes for
women requires careful consideration of not only which test is
used (PAP, LBC, or HPV) but at which stage in the screening/
testing process (e.g., primary, triage, or follow-up) would it
provide the greatest beneﬁt. All this, while taking into account
age, risk, and the progression and regression of HPV infection.
Among the 21 algorithms considered, 3-year PAP + HPV + PAP-
age emerges as the algorithm that provides the best balance and
offers the best value for money.
Source of ﬁnancial support: Supported by a ﬁnancial contribution from
Health and Wellness under the auspices of the Alberta Health Technolo-
gies Decision Process initiative: the Alberta Model for health technology
assessment and policy analysis. The views expressed herein do not neces-
sarily represent the ofﬁcial policy of Alberta Health and Wellness.
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